Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2018 16:01 ET | Source: G1 Therapeutics

G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update

Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October Initiated Phase 2a enrollment of lerociclib (G1T38) in...
August 07, 2018 06:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D.,...
August 01, 2018 06:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
July 09, 2018 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel

RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive...
June 08, 2018 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Appointment of New Members to the Board of Directors

RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have...
June 02, 2018 09:00 ET | Source: G1 Therapeutics

G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a...
May 16, 2018 17:07 ET | Source: G1 Therapeutics

G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a...
May 03, 2018 16:01 ET | Source: G1 Therapeutics

G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update

U.S. and European regulatory meetings scheduled based on positive trilaciclib Phase 2a myelopreservation data Preliminary data from G1T38 Phase 1b trial in breast cancer to be presented at ASCO on...
May 01, 2018 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018

RESEARCH TRIANGLE PARK, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
April 26, 2018 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018

RESEARCH TRIANGLE PARK, N.C., April 26, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced it will host a webcast and conference call to...